Provider Briefing: Clomid Availability in 2026

Clomiphene Citrate — better known by the brand name Clomid — remains a cornerstone of ovulation induction therapy and is increasingly prescribed off-label for male hypogonadism. After several years of supply chain instability, providers need a clear picture of where things stand and how to help patients navigate access challenges.

This briefing covers the current availability landscape, prescribing considerations, cost factors, and tools to streamline patient access to Clomiphene in 2026.

Shortage Timeline: How We Got Here

Understanding the supply chain history helps contextualize current availability patterns:

• 2019: ASHP first listed Clomiphene Citrate tablets on its drug shortage database, citing manufacturer supply issues.
• 2022 (early): Par Pharmaceuticals discontinued their generic clomiphene citrate unit-dose blister pack (NDC 49884-0701-55), removing a significant source from the market.
• September 2022: Cosette Pharmaceuticals acquired the brand-name Clomid product from Endo/Par and began distribution in October 2022.
• 2023-2024: Supply gradually stabilized under Cosette's manufacturing and distribution. However, inconsistent pharmacy stocking patterns persisted, particularly at chain pharmacies that had reduced Clomid inventory during the shortage period.
• 2025-2026: Clomid is not currently listed on the FDA Drug Shortage Database. Both brand and generic formulations are in production. However, localized availability gaps continue due to pharmacy-level inventory decisions and limited generic manufacturer participation.

Prescribing Implications

The post-shortage landscape has several implications for how providers approach Clomiphene prescribing:

Generic vs. Brand Considerations

Generic Clomiphene Citrate remains available from several manufacturers, though the number of producers is smaller than for many other generic medications. Brand-name Clomid from Cosette Pharmaceuticals offers a consistent supply with a patient savings program. When writing prescriptions:

• Allowing generic substitution maximizes pharmacy flexibility in sourcing available product.
• If patients report repeated difficulty with generic availability, the brand product with the Cosette savings card (myclomid.com/savings) may offer a more reliable alternative at a managed cost.

Letrozole as First-Line for PCOS

The American Society for Reproductive Medicine (ASRM) and multiple clinical guidelines now support Letrozole (Femara) as first-line ovulation induction therapy for PCOS. Key advantages for prescribers include:

• Higher ovulation and live birth rates in PCOS populations compared to Clomiphene
• Lower multiple pregnancy rates
• Shorter half-life with faster clearance
• Widely available generic at significantly lower cost ($10-$30 per cycle)
• No endometrial thinning effect

For patients without PCOS or those specifically benefiting from Clomiphene's mechanism, Clomid remains appropriate and effective.

Off-Label Prescribing for Male Hypogonadism

Clomiphene use for male hypogonadism and male infertility continues to grow, supported by AUA guidelines that conditionally recommend it as an alternative to exogenous testosterone. Typical off-label dosing is 25-50 mg daily or every other day. Providers should be aware that:

• This growing use contributes to overall demand pressure.
• Male patients may face fewer pharmacy stocking issues since they typically fill at pharmacies accustomed to ordering broader medication inventories.
• Enclomiphene (the trans-isomer of Clomiphene) is under investigation as a targeted alternative for this population but is not yet FDA-approved.

Current Availability Picture

In 2026, Clomiphene availability can be characterized as adequate nationally but inconsistent locally. Key patterns include:

• Chain pharmacies (CVS, Walgreens, Rite Aid) may not stock Clomid routinely if local demand is low. Most can order within 1-2 business days.
• Independent pharmacies may maintain stock more reliably, particularly those serving fertility clinic patient populations.
• Specialty fertility pharmacies typically maintain consistent Clomiphene inventory as a core product line.
• Regional variation: Availability varies significantly by geography. Urban areas with multiple pharmacy options generally have better access than rural areas.

Cost and Access Landscape

Cost remains a factor in patient access, particularly given the inconsistent insurance coverage of fertility medications:

Current Pricing (2026)

• Brand Clomid (30 tablets, 50 mg): $101-$250 retail
• Generic Clomiphene Citrate (30 tablets, 50 mg): $30-$115 with discount card; $80-$150 retail without coupons
• Cosette Savings Card: As low as $70 with commercial insurance; $135 for cash-pay patients
• Generic with insurance: Typically $10-$30 copay on preferred formulary tiers

Insurance Coverage Considerations

• Coverage of fertility medications varies dramatically by plan and state mandate. Twenty states have some form of fertility insurance mandate, but scope varies widely.
• Generic Clomiphene is typically on preferred formulary tiers when covered.
• Brand Clomid may require prior authorization or step therapy through generic first.
• Some plans exclude fertility medications entirely, even in states with mandates, due to plan type exemptions (self-insured ERISA plans, for example).

Patient Assistance

There is no dedicated manufacturer patient assistance program from Cosette for uninsured patients. However, providers can direct patients to:

• NeedyMeds.org and RxAssist.org for third-party assistance programs
• Discount cards (GoodRx, SingleCare) for significant savings on generic Clomiphene
• The Cosette savings card at myclomid.com/savings for brand-name cost reduction

For a comprehensive cost-saving resource to share with patients, see: How to Save Money on Clomid in 2026.

Tools and Resources for Providers

Several tools can help streamline the process of connecting patients with available Clomid:

Medfinder for Providers

Medfinder allows providers and their staff to quickly identify pharmacies with Clomiphene in stock near the patient's location. This can be integrated into the prescription workflow to avoid sending patients to a pharmacy that doesn't have the medication on hand.

Proactive Prescription Routing

Consider these workflow adjustments to reduce patient access friction:

1. Check availability before sending the prescription — use Medfinder or call the patient's preferred pharmacy to confirm stock.
2. Establish relationships with 1-2 pharmacies that reliably stock Clomid and can serve as backup options.
3. Provide patients with a backup plan — give them the pharmacy savings card information and suggest alternative pharmacies at the time of prescribing.
4. Consider e-prescribing to specialty pharmacies when patients report difficulty at chain locations.

Alternative Prescribing Pathway

For an overview of alternative medications to consider when Clomid is unavailable or clinically inappropriate, see: How to Help Your Patients Find Clomid in Stock: A Provider's Guide.

Looking Ahead

Several developments may influence the Clomiphene landscape in the coming years:

• Enclomiphene development: If approved for male hypogonadism, enclomiphene could reduce off-label Clomid demand from the urology and endocrinology sectors.
• Expanded generic competition: Additional ANDA approvals for generic Clomiphene could improve supply diversity and reduce pricing.
• Telehealth growth: Continued expansion of fertility telehealth services will increase prescription volume but also improve access for patients in underserved areas.
• Letrozole adoption: As Letrozole continues to gain clinical preference for PCOS, Clomid demand in this population may moderate, easing supply pressure.

Final Thoughts

Clomid remains an effective, affordable, and important medication for both female infertility and male hypogonadism. While the formal shortage has resolved, providers play a key role in helping patients navigate the uneven availability landscape. Proactive prescription routing, familiarity with alternative agents, and awareness of cost-saving tools can significantly reduce the burden on patients.

Visit Medfinder for Providers to access real-time pharmacy stock information and streamline your prescribing workflow. For a complete provider toolkit on helping patients find and afford Clomid, see our provider's guide to saving patients money on Clomid.